Cara Therapeutics

Cara Therapeutics is a biopharmaceutical company founded in 2004, dedicated to transforming the treatment of pruritus to improve the lives of patients. The company's focus lies in the development of an oral formulation of difelikefalin, a selective, peripherally acting, non-scheduled kappa opioid receptor agonist, with the aim of treating chronic pruritus associated with notalgia paresthetica (NP). This neuropathy, affecting the upper back, currently lacks FDA-approved therapies. Cara Therapeutics is currently engaged in a Phase 2/3 clinical program for NP, with topline results from the dose-finding portion expected in the third quarter of 2024. Moreover, the company has also successfully developed an IV formulation of difelikefalin, which has received approval in the United States, EU, and multiple other countries for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. This IV formulation has been out-licensed worldwide. Notably, Cara Therapeutics secured a $40.00M Post-IPO Debt investment on 02 November 2023, with HealthCare Royalty Partners as the investors. The company's tireless efforts to address unmet medical needs in the treatment of pruritus, along with its strong partnerships and successful fund acquisitions, position it as a promising player in the biotechnology and healthcare industries.